

Schaffhausen, February 5, 2013

**Announcement according to Art. 9 and Art. 21 SESTO-FINMA
Disclosure of shareholdings**

On January 31, 2013, pursuant to Art. 9 and Art. 21 SESTO-FINMA, The Bank of New York Mellon Corporation, New York, USA, has announced to BB Biotech AG, Schaffhausen, Switzerland, a change to the composition of the Group. Since December 4, 2012, BNY Mellon Investment Management Holdings LLC is an additional indirect holder of registered shares BB Biotech AG (ISIN CH0038389992).

The Bank of New York Mellon Corporation, New York, USA, held 1 232 022 voting rights (9.48% of the proportion of voting rights) as per December 4, 2012, indirectly by the companies listed below:

Direct Holders:

- Newton Investment Management Ltd., London, England
- BNY Mellon Service Kapitalanlage-Gesellschaft mbH, Frankfurt am Main, Germany
- Meriten Investment Management GmbH (Formerly WestLB Mellon Asset Management Kapitalanlage-Gesellschaft mbH), Düsseldorf, Germany

Indirect Holders:

- The Bank of New York Mellon, New York, USA
- MBC Investments Corporation, Greenville, Delaware, USA
- Mellon International Holdings S.a.r.l., Luxembourg
- BNY Mellon International Asset Management Group Limited, London, England
- Newton Management Limited, London, England
- The Bank of New York Mellon SA/NV, Brussels, Belgium
- Mellon JV Limited, London, England
- BNY Mellon Investment Holdings (Germany) Limited, London, England
- BNY Mellon Investment Management Holdings LLC, London, England

For further information, please contact:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Thomas Egger, Tel. +41 44 267 67 09, teg@bellevue.ch
www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with CHF 1.3 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.